Assessing Combined Bevacizumab-Mitomycin C Use During Ahmed Valve Revision in Recurrent Pediatric Glaucoma

Evaluation of Combined Bevacizumab-Mitomycin C Use During Ahmed Valve Revision in Recurrent Pediatric Glaucoma

Status

Completed

Phases

Early Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06983704

Acronym

MMC glaucoma

Enrollment

Registered

2025-05-21

Start date

2024-02-09

Completion date

2025-02-15

Last updated

2025-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pediatric Glaucoma

Keywords

Pediatric glaucoma, Ahmed valve, bevacizumab, mitomycin C

Brief summary

To asess the efficacy and safety of combining subconjunctival bevacizumab with mitomycin C (MMC) during AGV revision surgery in pediatric patients with recurrent glaucoma.

Detailed description

Recurrent pediatric glaucoma following Ahmed Glaucoma Valve (AGV) implantation presents a therapeutic challenge. This study evaluates the efficacy and safety of combining subconjunctival bevacizumab with mitomycin C (MMC) during AGV revision surgery in pediatric patients with recurrent glaucoma.

Interventions

PROCEDUREAGV plate

AGV plate using a 27-gauge needle

PROCEDUREbevacizumab injection

subconjunctival injection of bevacizumab

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Investigator)

Eligibility

Sex/Gender

ALL

Age

No minimum to 12 Years

Healthy volunteers

Inclusion criteria

* children under 12 years with previous AGV implantation for primary congenital glaucoma

Exclusion criteria

* age \>12 years, eyes with no light perception, and those with prior cyclodestructive procedures.

Design outcomes

Primary

Measure	Time frame	Description
surgical success	for 12 months	IOP ≤ 21 mmHg and ≥ 5 mmHg without medications

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026